KYVERNA THERAPEUTICS
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
KYVERNA THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Therapeutics
Founded:
2018-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.kyvernatx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
110 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Parthenon Therapeutics
Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Westlake Village BioPartners
Westlake Village BioPartners investment in Series B - Kyverna Therapeutics
Hudson Bay Capital Management
Hudson Bay Capital Management investment in Series B - Kyverna Therapeutics
RTW Investments LLC
RTW Investments LLC investment in Series B - Kyverna Therapeutics
Vida Ventures
Vida Ventures investment in Series B - Kyverna Therapeutics
The Argentum Group
The Argentum Group investment in Series B - Kyverna Therapeutics
Gilead Sciences
Gilead Sciences investment in Series B - Kyverna Therapeutics
CAM Capital
CAM Capital investment in Series B - Kyverna Therapeutics
Insight Partners
Insight Partners investment in Series B - Kyverna Therapeutics
LYFE Capital
LYFE Capital investment in Series B - Kyverna Therapeutics
Intellia Therapeutics
Intellia Therapeutics investment in Series B - Kyverna Therapeutics
Key Employee Changes
Official Site Inspections
http://www.kyvernatx.com Semrush global rank: 7.27 M Semrush visits lastest month: 548
- Host name: 37.120.75.34.bc.googleusercontent.com
- IP address: 34.75.120.37
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Kyverna Therapeutics"
Mission & Values | Kyverna
The Bedrock of Our Organization. Bring Intellectual Rigor. We ask thoughtful questions to respectfully advance breakthrough innovations, guide decision-making and deliver …See details»
Kyverna Therapeutics - Crunchbase Company Profile
Contact Email [email protected] KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic …See details»
Kyverna Therapeutics - LinkedIn
Kyverna Therapeutics | 18,974 followers on LinkedIn. Harnessing the power of cell therapy in autoimmune disease. | Kyverna is a patient-centered, clinical-stage biopharmaceutical …See details»
Kyverna is a Clinical-Stage Biopharmaceutical Company …
Discover Kyverna, a patient-centered, clinical-stage biopharmaceutical company with active, ongoing clinical trials for multiple autoimmune diseases at different locations across the world.See details»
Kyverna Therapeutics Strengthens Leadership Team to Accelerate …
Key Leadership Appointments Bring New Skills and Capabilities to Organization . EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage …See details»
Kyverna Therapeutics Announces Leadership Update | Kyverna …
Sep 16, 2024 "Since its inception in 2018, Kyverna has made tremendous progress in pursuit of a paradigm shift for patients with autoimmune disease. Kyverna today sits on the precipice of …See details»
Kyverna Therapeutics - Company Profile & Staff Directory
Kyverna Therapeutics is a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic …See details»
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Oct 21, 2024 Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from …See details»
Kyverna Therapeutics Provides Business Update and Reports Full …
Kyverna's pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B …See details»
Kyverna Therapeutics Strengthens Leadership Team to Accelerate …
EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients …See details»
Karen Walker - Kyverna Therapeutics
Karen Walker is Chief Technology Officer at Kyverna Therapeutics. Ms. Walker has broad and deep industry experience developing biopharmaceuticals and cell and gene therapy (CGT) …See details»
Kyverna Therapeutics - Golden
Kyverna Therapeutics is a cell therapy company developing therapies for autoimmune diseases. The company applies T cell engineering and synthetic biology technologies to develop …See details»
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Oct 21, 2024 “We are delighted to welcome Mert to Kyverna’s Board of Directors as we continue to advance KYV-101 into later stages of development and build on Kyverna’s CAR T …See details»
Kyverna Therapeutics Secures $25 Million Series A Funding from …
Jan 13, 2020 As part of this financing, Fred Cohen, M.D., D.Phil., Co-Founder and Senior Managing Director of Vida Ventures will serve as Chairman of the Board. Beth Seidenberg, M ...See details»
Kyverna Therapeutics Announces Leadership Update
Sep 16, 2024 Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.See details»
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board …
Sep 15, 2021 EMERYVILLE, Calif., September 15, 2021 – Kyverna Therapeutics, Inc., a cell therapy company focused on engineering a new class of therapies for serious autoimmune …See details»
Kyverna's KYV-101 Receives U.S. FDA Clearance for Treatment of …
"As a patient-centered organization, we are thrilled to see KYV-101 being cleared for a large patient demographic as part of our KYSA-7 trial," said Peter Maag, Ph.D., chief executive …See details»
Kyverna Therapeutics Bolsters Leadership Team with Cell Therapy ...
Dec 13, 2024 Kyverna Therapeutics announced three key leadership appointments to support its next growth phase in developing cell therapies for autoimmune diseases.Dan Maziasz joins as …See details»
Kyverna Therapeutics Strengthens Leadership Team to Accelerate …
Dec 13, 2024 Key Leadership Appointments Bring New Skills and Capabilities to Organization. EMERYVILLE, Calif., Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a …See details»